NCT06906367Recruiting
A Study of Patients With Fabry Disease (US Specific)
A Prospective, Observational Study of Patients With Fabry Disease (US Specific)
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 450 (estimated)
- First submitted
- 26 Mar 2025
- Start date
- 13 Feb 2026
- Primary completion date
- 30 Jun 2032
- Lead sponsor
- Amicus Therapeutics
- Diseases
- Fabry disease
- NCT number
- NCT06906367
What you commit to
- Study type: Observational
- Planned participants: 450
- From 13 Feb 2026 to the primary completion date, 30 Jun 2032
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Patients who currently are participating in a clinical trial of any investigational medicinal product or device at the time of enrollment
Criteria the registry did not label
- Migalastat-treated patients (Commercial only participants)
- Patients with Fabry disease 18 years or older with amenable GLA variants who have commenced commercial migalastat treatment within 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL/min/1.73 m2 at the time of enrollment and are still taking migalastat at the time of enrollment, or who are starting migalastat at the time of enrollment, excluding those who participated in a prior migalastat clinical trial
- Patients who show a decline in their Fabry disease symptomatology based on any of the following:
- a decrease in annualized rate of decline eGFRCKD-EPI of ≥ 2 mL/min/1.73 m2 during the 2 years prior to enrollment
- microalbuminuria/macroalbuminuria (≥ 30 mg/24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg/g (via spot urine collection) at any time prior to or at enrollment
- proteinuria (\> 0.5 g/g UPCR) any time prior to or at enrollment
- males with classic Fabry disease phenotype
- Migalastat-treated patients who are not considered to be in renal decline (Commercial migalastat users only)
- 1\. Patients with Fabry disease with amenable GLA variants who have been on commercial migalastat regardless of the duration of treatment
- Migalastat-treated patients (Prior clinical trial participants)
- Patients with Fabry disease 18 years or older who had commenced treatment with migalastat while in a clinical trial and were exposed to treatment for at least 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL/min/1.73 m2 at the time of enrollment, and who are still taking migalastat at the time of enrollment, having switched to commercial product
- Untreated patients
- Patients with Fabry disease 18 years or older with amenable GLA variants, who have never been on treatment for Fabry disease, who have an eGFR greater than or equal to 30 mL/min/1.73 m2 at the time of enrollment, and who meet local treatment guidelines for Fabry disease
- Patients who show a decline in their Fabry disease symptomatology based on any of the following:
- a decrease in annualized rate of decline eGFRCKD-EPI of ≥ 2 mL/min/1.73 m2 during the 2 years prior to enrollment
- microalbuminuria/macroalbuminuria (≥ 30 mg/24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg/g (via spot urine collection) at any time prior to or at enrollment
- proteinuria (\> 0.5 g/g UPCR) any time prior to or at enrollment
- males with classic Fabry disease phenotype
- ERT-treated patients
- Patients with Fabry disease 18 years or older who have commenced ERT within 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL/min/1.73 m2 at the time of enrollment and are still being treated with ERT at the time of enrollment, and who have amenable GLA variants
- Patients who show a decline in their Fabry disease symptomatology based on any of the following:
- a decrease in eGFRCKD-EPI annualized rate of decline of ≥ 2 mL/min/1.73 m2 during the 2 years prior to enrollment
- microalbuminuria/macroalbuminuria (≥ 30 mg/24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg/g (via spot urine collection) at any time prior to or at enrollment
- proteinuria (\> 0.5 g/g UPCR) any time prior to or at enrollment
- males with classic Fabry disease phenotype
- All patients 1. All treated and untreated patients with Fabry disease who are enrolled in the study must be able to understand and provide written informed consent or assent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory Genetics Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| UAB Nephrology Research Clinic at Paula Building Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
| Renal Disease Research Institute Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Lysosomal and Rare Disorders Research and Treatment Center, Inc Coordinator of this site? Confirm its status | Fairfax | United States | Recruiting |
| Arkansas Children's Hospital Coordinator of this site? Confirm its status | Little Rock | United States | Recruiting |
| New York-Presbyterian Morgan Stanley Children's Hospital - Columbia University Medical Center Coordinator of this site? Confirm its status | New York | United States | Not yet recruiting |
| UPMC Children's Hospital of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.